A real-world study found that 25% of patients on pemigatinib had extrahepatic cholangiocarcinoma, a subtype where the drug's FGFR2 fusion target is historically rare. This significant deviation from established biology suggests potential issues with physician-abstracted data, such as mislabeling or referral bias, highlighting the need for cautious interpretation of real-world patient cohorts.

A key side effect of the FGFR inhibitor erdafitinib is central serous retinopathy, presenting as blurred vision. Standard of care involves a baseline ophthalmologic exam before starting treatment. If blurred vision occurs, treatment should be held immediately, but the condition is typically reversible and manageable with dose reduction.

The failure of an adjuvant trial for the TKI pazopanib was likely caused by a protocol change that reduced the dose to manage transaminitis. While well-intentioned to improve tolerability and adherence, the lower dose was sub-therapeutic. This serves as a critical lesson that managing side effects by compromising dose can nullify a drug's potential efficacy.

Pre-approval clinical trials, run by drug makers, reported a sub-2% discontinuation rate due to side effects. Post-market observational data reveals a starkly different reality: approximately 10% of patients stop taking statins due to adverse effects like muscle pain.

Due to significant ocular toxicity affecting most patients, the approved starting dose for belantumab is likely not optimal long-term. Effective management requires clinicians to proactively hold, delay, and reduce doses at the first sign of side effects, meaning real-world application will differ from the initial protocol.

The study utilized "interruption-free survival" as a primary endpoint, a pragmatic measure derived from real-world data. This serves as a valuable surrogate for treatment toxicity, as clinicians typically pause treatment in response to adverse events, providing a quantifiable measure of a drug's real-world tolerability.

The enzalutamide arms saw discontinuation rates of 20-25% due to adverse events. This high rate reflects a different risk calculation for patients who feel healthy and are asymptomatic. Unlike in advanced disease where patients tolerate more toxicity, this population has a very low threshold for side effects, making early intervention a significant trade-off.

A critical distinction exists between a clinical adverse event (AE) and its impact on a patient's quality of life (QOL). For example, a drop in platelet count is a reportable AE, but the patient may be asymptomatic and feel fine. This highlights the need to look beyond toxicity tables to understand the true patient experience.

Real-world data for pemigatinib in cholangiocarcinoma showed a higher response rate (59%) than the pivotal FITE-202 trial (36%). This discrepancy likely stems from the lack of standardized, centrally reviewed imaging in real-world settings, which can inflate perceived response. Comparable progression-free survival across both settings supports this interpretation.